申请人:University of Dundee
公开号:US20140148452A1
公开(公告)日:2014-05-29
The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.
该发明涉及按照式(I)的吗啡啉衍生物或其立体异构体或药用可接受的盐或溶剂,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、m和n如规范中定义。这些化合物是G蛋白偶联受体的拮抗剂、反向激动剂或激动剂,例如多巴胺D4和5HT1a。该发明还涉及包括这些化合物的药物组合物和涉及这些化合物和组合物的方法。该发明的化合物和组合物特别可用于治疗疾病和障碍,如神经系统和神经退行性疾病;或作为设计和选择进一步治疗化合物的引导化合物。